Researchers have identified early cancer markers in previously healthy pancreatic tissue, according to a study published in a leading oncology journal. The findings, which challenge existing understanding of pancreatic cancer development, were reported by a team at the Max Planck Institute for Molecular Cell Biology and Genetics in Dresden, Germany.
What the Study Found
The research team analyzed tissue samples from 42 individuals without a diagnosed pancreatic cancer diagnosis. Using advanced genomic sequencing, they detected molecular alterations typically associated with pancreatic tumors, including mutations in the KRAS gene and epigenetic changes linked to cancer progression. These markers were present in 31% of the samples, according to the study.
Lead author Dr. Lena Hartmann noted that the markers were not indicative of active cancer but suggested a “pre-cancerous state” that could be detectable years before clinical symptoms emerge. The team compared the findings to a control group of 28 individuals with no genetic risk factors, finding similar markers in 14% of that group.
Context and Implications
Pancreatic cancer remains one of the deadliest cancers, with a five-year survival rate of less than 10%. Early detection is critical, as the disease often spreads before symptoms appear. Current screening methods rely on imaging and blood tests that typically identify tumors at later stages.
The study’s results align with emerging research on “field cancerization,” a theory that healthy tissue adjacent to tumors may harbor precancerous changes. However, this is the first study to document such changes in completely asymptomatic individuals, according to the researchers.
Expert Reactions
Dr. Marcus Richter, a pancreatic cancer specialist at Heidelberg University Hospital, called the findings “provocative but preliminary.” He emphasized that the study does not prove the markers cause cancer but suggests they could serve as biomarkers for risk assessment.
“This could revolutionize screening if we can differentiate between harmless genetic variations and true precursors,” Richter said. “But we need larger studies to confirm these results and understand their clinical significance.”
Limitations and Unanswered Questions
The study’s small sample size and lack of long-term follow-up data limit its conclusions. Researchers acknowledged that the presence of these markers does not guarantee cancer development, and further research is needed to determine their predictive value.
Another concern is the potential for overdiagnosis. If these markers are widespread in the general population, widespread screening could lead to unnecessary medical interventions, experts warned.
What’s Next
The research team plans to expand the study to 500 participants, including individuals with a family history of pancreatic cancer. They also aim to develop a blood test that could detect these markers noninvasively. A follow-up study is scheduled to begin in early 2025, according to the institute.
